Survodutide
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
Boehringer Ingelheim · Phase 1 · Completed · Enrollment 88
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| BI 1820237 treatment group | Obesity or overweight | n/r | n/r | n/r | n/r |
| Placebo group | Obesity or overweight | n/r | n/r | n/r | n/r |
| BI 1820237 + semaglutide treatment group | Obesity or overweight | n/r | n/r | n/r | n/r |
| placebo + semaglutide group | Obesity or overweight | n/r | n/r | n/r | n/r |
| BI 1820237 + BI 456906 treatment group | Obesity or overweight | n/r | n/r | n/r | n/r |
| placebo + BI 456906 group | Obesity or overweight | n/r | n/r | n/r | n/r |